Fexofenadine Impurity F T-3'-TBDMS-Bz-rA The no observed adverse effect

The no observed adverse effect levels (NOAEL) of 100 mg/kg/day is approximately 93 times the MRHD based on AUC

InChi: InChI=1S/C54H83N13O13/c1-9-29(6)43(66-49(75)39(22-28(4)5)62-46(72)36(55)21-27(2)3)51(77)64-40(23-32-16-18-34(70)19-17-32)48(74)63-41(24-33-25-59-37-14-11-10-13-35(33)37)47(73)60-30(7)45(71)65-42(26-68)50(76)67-44(31(8)69)52(78)61-38(53(79)80)15-12-20-58-54(56)57/h10-11

Gypenoside XLIX is a selective peroxisome proliferator-activated receptor (PPAR)-alpha activator and inhibits cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) overexpression and hyperactivity in human endothelial cells

Smiles: CC(C)=CCC/C(/C)=C/CC/C(/C)=C/CC/C(/C)=C/CC/C(/C)=C/CC/C(/C)=C/CC/C(/C)=C/CC/C(/C)=C/CC/C(/C)=C/CC1C(=O)C(OC)=C(OC)C(=O)C=1C

InChiKey: FKWHSTNULIKFMI-UHFFFAOYSA-N

Fexofenadine Impurity F T-3'-TBDMS-Bz-rA The no observed adverse effectFexofenadine Impurity F is the impurity of Fexofenadine. Fexofenadine, a H1R antagonist, is an anti allergic agent used in seasonal allergic rhinitis and chronic idiopathic urticarial. Product information CAS Number: 185066 33 5 Molecular Weight: 487. 63 Formula: C31H37NO4 Chemical Name: 2 (4 {1 hydroxy 4 [4 (hydroxydiphenylmethyl)piperidin 1 yl]butyl}phenyl)propanoic acid Smiles: CC(C1C=CC(=CC=1)C(O)CCCN1CCC(CC1)C(O)(C1C=CC=CC=1)C1C=CC=CC=1)C(O)=O